Lixin You
Overview
Explore the profile of Lixin You including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Y, Liu C, You L, Li X, Chen G, Fan J
J Cell Mol Med
. 2023 Feb;
27(5):634-649.
PMID: 36753396
Ovarian cancer has the highest facility rate among gynaecological tumours. Current therapies including PARP inhibitors have a defect that ovarian tumour is easy to recurrent and become resistant to therapy....
2.
Hu D, Guo E, Yang B, Qin X, Fu Y, Fan J, et al.
Cancer Sci
. 2022 Jun;
113(8):2849-2861.
PMID: 35661486
Although resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) has gradually become a major challenge in the maintenance therapy for high-grade serous ovarian carcinoma (HGSOC), there are no universal indicators for resistance...
3.
Xiao R, You L, Zhang L, Guo X, Guo E, Zhao F, et al.
Adv Sci (Weinh)
. 2022 May;
9(21):e2105469.
PMID: 35619328
Targeting the G2/M checkpoint mediator WEE1 has been explored as a novel treatment strategy in ovarian cancer, but mechanisms underlying its efficacy and resistance remains to be understood. Here, it...
4.
Yang L, Zhang Z, Hu X, You L, Khan R, Yu Y
Molecules
. 2022 Apr;
27(8).
PMID: 35458693
Wild fruits have increasingly been investigated as part of recent searches for food products with a high antioxidant activity. In this study, wild edible berberis collected from three different provinces...
5.
Liu C, Huang Y, Cui Y, Zhou J, Qin X, Zhang L, et al.
Front Immunol
. 2022 Jan;
12:799171.
PMID: 35095879
Background: Ovarian cancer (OC) is one of the most lethal gynecologic cancers. Growing evidence has proven that CDK4/6 plays a key role in tumor immunity and the prognosis of many...
6.
Liu C, Huang Y, Qin T, You L, Lu F, Hu D, et al.
Cancer Lett
. 2021 Dec;
528:31-44.
PMID: 34942306
The CDK4/6 inhibitor, palbociclib has recently entered clinic-trial stage for breast cancer treatment. However, translating its efficacy to other solid tumors has been challenging, especially for aggressive solid tumors. We...
7.
Qin T, Guo E, Lu F, Fu Y, Liu S, Xiao R, et al.
Aging (Albany NY)
. 2021 Dec;
13(23):24943-24962.
PMID: 34862879
Ongoing pandemic and potential resurgence of Coronavirus disease 2019 (COVID-19) has prompted urgent efforts to investigate the immunological memory of convalescent patients, especially in patients with active cancers. Here we...
8.
Guo E, Xiao R, Wu Y, Lu F, Liu C, Yang B, et al.
J Exp Med
. 2021 Nov;
219(1).
PMID: 34825915
Targeted therapies represent attractive combination partners with immune checkpoint blockade (ICB) to increase the population of patients who benefit or to interdict the emergence of resistance. We demonstrate that targeting...
9.
Wang Z, Guo E, Yang B, Xiao R, Lu F, You L, et al.
Gynecol Oncol
. 2021 Sep;
163(2):358-363.
PMID: 34507827
Background: Gynecologic cancers seriously threaten women's life and health. This study aims to assess the long-term trends of mortality from the three major gynecologic cancers in China and to examine...
10.
Wang Z, Xiao R, Huang J, Qin X, Hu D, Guo E, et al.
Microb Ecol
. 2021 Aug;
84(1):302-313.
PMID: 34405250
The vaginal microbiota is closely related to HPV infection and cervical cancer (CC), but its relationship with platinum-based chemotherapy responsiveness is unknown. The study aimed to investigate the vaginal microbiota...